Lupin has informed that it has enclosed a Press Release on 28th September 2020 as regards launch by the Company of Fosaprepitant for Injection, 150 mg Single-Dose Vial, having received an approval from the US FDA earlier.
The above information is a part of company’s filings submitted to BSE.